Skip to main content
. 2019 Sep 3;15:83–100. doi: 10.1016/j.omtm.2019.08.012

Figure 2.

Figure 2

Liver Transduction Controls Preexisting Anti-hSGCA Immune Response in C57BL/6J Mice

(A) Eight-week-old C57BL/6J mice received at day 0 an intramuscular injection (TA) of 2.5 × 109 vg/mouse of AAV6-SPc5.12-hSGCA vector and at day 0 or day 15 an intravenous injection (IV) of 1 × 1011 vg/mouse of AAV9-hAAT-hSGCA (Muscle-Liver day 0 and Muscle-Liver day 15, respectively). In parallel, two groups of mice injected intramuscularly at day 0 with PBS or 2.5 × 109 vg/mouse of AAV6-SPc5.12-hSGCA vector were used as controls (Control and Muscle groups, respectively). One month after treatment, mice were sacrificed and tissues collected. (B) HPS (upper panel, scale bar: 100 μm) and anti-hSGCA (green), CD8 (red), and DAPI (blue) immunostaining (lower panel, scale bar: 50 μm) performed on TA muscle. White arrows indicate CD8 cells. (C and D) CD8 (C) and IFN-γ (D) mRNA measured in TA. (E) Vector genome copy number (VGCN) per diploid genome measured in TA. Data were expressed as mean ± SD. Statistical analyses were performed by ANOVA (*p < 0.05; n = 4 per group).